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Non-familial small bowel carcinomas are relatively rare and have a poor prognosis. Two small bowel carcinoma
subsets may arise in distinct immune-inflammatory diseases (celiac disease and Crohn’s disease) and have been
recently suggested to differ in prognosis, celiac disease-associated carcinoma cases showing a better outcome,
possibly due to their higher DNA microsatellite instability and tumor-infiltrating T lymphocytes. In this study, we
investigated the histological structure (glandular vs diffuse/poorly cohesive, mixed or solid), cell phenotype
(intestinal vs gastric/pancreatobiliary duct type) and Wnt signaling activation (β-catenin and/or SOX-9 nuclear
expression) in a series of 26 celiac disease-associated small bowel carcinoma, 25 Crohn’s disease-associated
small bowel carcinoma and 25 sporadic small bowel carcinoma cases, searching for new prognostic parameters.
In addition, non-tumor mucosa of celiac and Crohn’s disease patients was investigated for epithelial precursor
changes (hyperplastic, metaplastic or dysplastic) to help clarify carcinoma histogenesis. When compared with
non-glandular structure and non-intestinal phenotype, both glandular structure and intestinal phenotype were
associated with a more favorable outcome at univariable or stage- and microsatellite instability/tumor-infiltrating
lymphocyte-inclusive multivariable analysis. The prognostic power of histological structure was independent of
the clinical groups while the non-intestinal phenotype, associated with poor outcome, was dominant among
Crohn’s disease-associated carcinoma. Both nuclear β-catenin and SOX-9 were preferably expressed among
celiac disease-associated carcinomas; however, they were devoid, per se, of prognostic value. We obtained
findings supporting an origin of celiac disease-associated carcinoma in SOX-9-positive immature hyperplastic
Correspondence: Dr A Vanoli, MD, Department of Molecular Medicine, University of Pavia, Via Forlanini 14, Fondazione IRCCS
Policlinico San Matteo, Pavia 27100, Italy.
E-mail: ale.vanol@virgilio.it
17These authors are co-contributing first authors.
Data in this study have been partially presented at the 2015 and 2017 annual meetings of the United States and Canadian Academy of
Pathology.
Received 6 February 2017; revised 22 March 2017; accepted 23 March 2017; published online 30 June 2017
Modern Pathology (2017) 30, 1453–1466
© 2017 USCAP, Inc All rights reserved 0893-3952/17 $32.00 1453
www.modernpathology.org
crypts, partly through flat β-catenin-positive dysplasia, and of Crohn’s disease-associated carcinoma in a
metaplastic (gastric and/or pancreatobiliary-type) mucosa, often through dysplastic polypoid growths of
metaplastic phenotype. In conclusion, despite their common origin in a chronically inflamed mucosa, celiac
disease-associated and Crohn’s disease-associated small bowel carcinomas differ substantially in histological
structure, phenotype, microsatellite instability/tumor-infiltrating lymphocyte status, Wnt pathway activation,
mucosal precursor lesions and prognosis.
Modern Pathology (2017) 30, 1453–1466; doi:10.1038/modpathol.2017.40; published online 30 June 2017
Small bowel carcinomas are relatively rare neo-
plasms, the majority of which arise sporadically,
while few cases are associated with genetic condi-
tions such as familial adenomatous polyposis, Lynch
and Peutz–Jeghers syndromes or may develop in
immune-mediated inflammatory conditions, such as
celiac disease or Crohn’s disease.1 Several small
bowel carcinoma studies are available concerning
their histological structure, cell phenotype, nuclear
β-catenin or p53 protein expression and TP53, KRAS,
PIK3CA, HER2 or microsatellite instability-related
gene mutation/methylation or copy number
alteration.2–6 These studies, however, deal mostly
with sporadic cases or with few cases from other
subgroups, with limited information on associated
background disease or specific tumor histogenesis,
progression and prognosis.
We recently collected a fairly large series of
patients with surgically resected celiac disease-
associated or Crohn’s disease-associated small bowel
carcinomas and identified a significantly better
overall and cancer-specific survival of celiac
disease-associated carcinoma patients compared
with Crohn’s disease-associated carcinoma patients,
with no substantial difference between these two
carcinoma subsets and sporadic ones, which showed
intermediate survival.7 Neither stage nor histopatho-
logical type and grade according to WHO 2010
classification criteria accounted for such behavior
difference, which was, however, attributed to the
higher prevalence of microsatellite instability status
found in celiac disease-associated carcinoma, in
accordance with previous observations.8,9 No other
molecular change, such as p53 overexpression or
TP53 gene mutation, and KRAS or PIK3CA gene
mutations, had a significant prognostic impact.
Results of potential clinico-pathological relevance
provided by previous studies are those suggesting a
prognostic relevance of tumor cell phenotype,3,10,11 a
selective tumor association with mucosal metaplas-
tic changes12 or dysplastic lesions13–15 and a patho-
genetic role of molecular changes affecting
microsatellite instability status,8,9,16,17 Wnt signaling
pathway18–20 or p53 gene involvement.5 In the
present study, we reinvestigated our small bowel
carcinoma series aiming to (a) look for any prog-
nostic influence of histopathological structure, with
special reference to tumor cell cohesion and stromal
desmoplasia, and tumor cell phenotype, according to
criteria already developed for the evaluation of
gastric cancer;21–23 (b) expand our analysis to Wnt
pathway activation signs such as nuclear β-catenin
and SOX-9 transcription factor expression, including
their correlation with microsatellite instability sta-
tus; and (c) gain new insights into cancer histogen-
esis, with special reference to the carcinogenetic
process at work in the inflamed non-tumor mucosa
of celiac disease-associated or Crohn’s disease-
associated small bowel carcinoma patients.
Materials and methods
Study Population
This retrospective study included 76 patients with
primary non-familial, non-ampullary small bowel
carcinoma, including 26 celiac disease-associated
small bowel carcinomas, 25 Crohn’s disease-
associated small bowel carcinomas and 25 small
bowel carcinomas arising sporadically, ie, without a
concomitant intestinal immune-mediated disorder.
The patients, enrolled for a former previous clinico-
pathological study, had surgical resection and
complete survival data from 20 tertiary referral
Italian Celiac or Inflammatory Bowel Disease Centers
participating in the Small Bowel Cancer Italian
Consortium.6 The main exclusion criteria for all
small bowel carcinoma subgroups were Lynch
syndrome, Peutz–Jeghers syndrome, familial adeno-
matous polyposis and juvenile polyposis. Neuroen-
docrine neoplasms were also excluded. This study
was approved by the Ethics Committee of the San
Matteo Hospital Foundation of Pavia.
Histology and Immunohistochemistry
Tissue samples were fixed in 4% formaldehyde and
processed in paraffin wax. Four-μm-thick sections
were stained with hematoxylin–eosin and all cases
were reinvestigated for histological findings. Histo-
logically, small bowel carcinomas were reclassified
as (a) glandular type (if470% of the tumor exhibited
glandular pattern), (b) diffuse/poorly cohesive cell
type (signet ring cell cancers or cancers showing
diffusely infiltrating, poorly cohesive cells, dis-
persed in a frequently desmoplastic stroma as single
elements or as small aggregates with little to no gland
formation, in 470% of the tumor), (c) mixed type
(characterized by a combination of both glandular
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and poorly cohesive cell/desmoplastic patterns, with
at least 30% each, within the same tumor) and solid
cancers (when they showed almost exclusively a
solid or trabecular pattern).21,22,24 Among solid
cancers, (d) medullary-type cancers (characterized
by tumor cells exhibiting prominent infiltration by T
lymphocytes and a pushing margin) were distin-
guished from the (e) non-medullary solid cases
lacking these features.22 Four small bowel carcino-
mas previously classified as ‘mucinous carcinomas’7
were included in the glandular (three cases) or
mixed (one case) type according to the predominant
structure of the neoplasm. All cases were also
checked for the presence of adjacent dysplastic
lesions and metaplastic features of the uninvolved
mucosa.
For immunohistochemistry, four-μm-thick sec-
tions were incubated at 4 °C for 18–20 h with specific
antibodies directed against: the gastric foveolar cell
marker MUC5AC (monoclonal, clone CLH2, Abcam),
the pancreatobiliary duct marker cytokeratin (CK) 7
(monoclonal, clone OV-TL 12/30, Dako), the pyloric
and Brunner’s gland marker MUC6 (monoclonal,
clone CLH5, Novocastra), as well as against intestinal
differentiation markers, including the transcription
factor CDX2 (monoclonal, clone DAK-CDX2, Dako),
the goblet cell marker MUC2 (monoclonal, clone
Ccp58, Santa Cruz Biotechnology), CK20 (monoclo-
nal, clone Ks20.8, Dako) and the small bowel brush
border marker CD10 (monoclonal, clone 56C6,
Dako). In addition, immunoreactions for C-terminal
β-catenin (monoclonal, clone 14/Beta-Catenin, BD);
for the transcription factor Sex-determining Region
Y-Box 9 (SOX-9, polyclonal, Millipore); for the
mismatch repair proteins, including MLH1 (mono-
clonal, clone ES05, Dako), MSH2 (monoclonal, clone
FE11, Dako), MSH6 (monoclonal, clone EP49, Dako)
and PMS2 (monoclonal, clone EP51, Dako); for p53
protein (monoclonal, clone DO7, Dako); for the
neuroendocrine marker chromogranin-A (monoclo-
nal, clone LK2H10, Ventana) and for CD3 (poly-
clonal, Dako) and CD8 (polyclonal, Dako) were also
performed. Immunoreactions were developed using
0.03% 3,3’ diaminobenzidine tetrahydrochloride
and sections were then counterstained with Harris’
hematoxylin.
For the assessment of tumor cell phenotype, only
cases with at least 10% immunoreactive cells were
regarded as positive with the exception of CDX-2, for
which a cutoff of 20% was applied.23 Cases with
nuclear accumulation of C-terminal β-catenin in at
least 10% of dysplastic/tumor cells was recorded as
positive and were also tested for the loss of nuclear
expression of N-terminal β-catenin (monoclonal,
clone E247, Abcam). Only relatively strong nuclear
SOX-9 immunoreactivity, with the same intensity as
the deepest intestinal crypt cells, was regarded as
positive. Immunostaining of mismatch repair pro-
teins in neoplastic cells was evaluated as positive or
negative. Tumor or dysplastic growths were consid-
ered negative when there was complete absence of
nuclear staining of neoplastic cells in the presence of
an internal positive control. A tumor was classified
as having high density of tumor-infiltrating lympho-
cytes when the mean number of CD3-positive tumor-
infiltrating lymphocytes per high-power field was
415, as previously reported.7,25 Tumor or dysplastic
lesions were considered p53 positive when ≥50% of
the cells showed strong nuclear p53 immunoreactiv-
ity. A central pathology review was performed by
two surgical pathologists specialized in gastrointest-
inal pathology (AV and ES).
Microsatellite Instability Analysis
Tumor DNA was obtained from formalin-fixed and
paraffin-embedded tissues using three representative
8 μm-thick sections of tumor samples. DNA was
extracted after manual microdissection using a
QIAamp DNA Formalin-Fixed, Paraffin-Embedded
Tissue Kit according to the manufacturer’s protocol
(Qiagen, Hilden, Germany). Microsatellite instability
analysis was performed using a pentaplex panel of
monomorphic mononucleotide repeats (BAT25,
BAT26, NR-21, NR-22 and NR-24) by the ABI PRISM
310 Genetic Analyzer (Applied Biosystems, Foster
City, CA, USA).
MLH1 Methylation Analysis
MLH1 methylation status was examined by pyrose-
quencing in small bowel carcinomas exhibiting loss
of MLH1 immunohistochemical expression as pre-
viously reported.7
Statistical Analysis
The distribution of biomarkers was reported as
counts and percentage and Fisher’s exact test was
used to compare them across clinical groups.
Cumulative survival was plotted according to the
Kaplan–Meier method. The follow-up extended from
the date of surgery to the date of death or last follow-
up. The association candidate prognostic factors and
tumor-related death was estimated by means of
univariable and multivariable Cox regression. The
choice of variables to be included in the multi-
variable model was decided a priori and was based
on the biological knowledge of the tumor. Hazard
ratios and their 95% confidence intervals were
computed. The proportional hazard assumption
was tested, based on Schoenfeld residuals. Model
discrimination was assessed with the Harrell’s c
statistic (the closer to 1, the better) and calibration
with the shrinkage coefficient (the closer to 1, the
better). A two-sided P-valueo0.05 was considered
statistically significant. For post hoc comparisons,
Bonferroni’s correction applies. Stata 14
(StataCorp, College Station, TX, USA) was used for
computation.
Modern Pathology (2017) 30, 1453–1466
Small bowel carcinomas in celiac or Crohn’s disease
A Vanoli et al 1455
Results
Histological Classification
Histological analysis showed predominance of
gland-forming tumors over diffuse, mixed glandu-
lar/diffuse, medullary or non-medullary solid cases
(Table 1 and Figure 1). Survival analysis of these five
tumor histotypes gave a trend for worse outcome of
diffuse, mixed and solid non-medullary compared
with glandular or medullary cases (Figure 2a). When
diffuse, mixed and solid histotypes were pooled in a
single group of 28 cases (Figure 2b), a significant
survival difference emerged for this group in
comparison with glandular cases (hazard ratio:
4.93, 2.23–10.89, Po0.001). Multivariable analysis
confirmed a significantly improved survival of
Table 1 Histological classification of the 76 small bowel carcinomas investigated
Histotype








Glandular 14 (54%) 13 (52%) 15 (60%) 42 (55%)
Medullary 4 (15%) 1 (4%) 1 (4%) 6 (8%)
Solid 3 (11.5%) 2 (8%) 3 (12%) 8 (11%)
Diffuse 2 (8%) 4 (16%) 1 (4%) 7 (13%)
Mixed 3 (11.5%) 5 (20%) 5 (20%) 13 (23%)
No significant histotype distributive difference among the clinical groups was found.
Figure 1 Small bowel carcinoma histotypes. (a) This glandular-type celiac disease-associated carcinoma is predominantly composed of
well-formed tubular structures. (b) This diffuse type celiac disease-associated carcinoma is characterized by poorly cohesive cells,
dispersed in a desmoplastic stroma as single elements or as small aggregates. (c, d) A mixed type Crohn’s disease-associated ileal
carcinoma characterized by a combination of both glandular and diffuse patterns within the same tumor. In panel (d), the same Crohn’s
disease-associated carcinoma expressing the gastric marker MUC5AC in both components. (e) A non-medullary solid-type celiac disease-
associated carcinoma composed of nests of large, eosinophilic and atypical cells without intratumor T-cell infiltration. (f) This medullary-
type celiac disease-associated carcinoma is characterized by solid/trabecular growth of cells, a pushing margin and prominent infiltration
by numerous T lymphocytes (see CD3 immunostaining in the inset).
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patients with glandular-type small bowel carcinoma,
independently of clinical group, tumor-infiltrating
lymphocyte density (or microsatellite instability)
and stage (Table 2).
Tumor Cell Phenotype
The distribution of the intestinal phenotypic markers
CDX2, MUC2, CK20 or CD10, the gastric marker
MUC5AC and the pancreatobiliary duct marker CK7
among small bowel carcinoma subsets is outlined in
Table 3, where 39 tumors with essentially intestinal
phenotype (ie, positive for CDX2, MUC2, CK20
and/or CD10, whereas negative for both MUC5AC
and CK7) were separated from the remaining 37
tumors expressing a metaplastic gastro-pancreat-
obiliary phenotype, either alone or admixed with
the intestinal one (ie, positive for MUC5AC and/or
CK7 while being positive or negative for CDX2,
MUC2, CK20 and CD10). A general predominance of
the intestinal phenotype among both celiac disease-
associated and sporadic cases and of the non-
intestinal (gastro-pancreatobiliary or mixed) pheno-
type among Crohn’s disease cases was observed
(Figure 3). Intestinal phenotype was more frequently
found in glandular (32/42, 76%) compared with
diffuse/mixed/solid cases (6/28, 21%, Po0.001). In
particular, 11 of the 13 mixed, 4 of the 7 diffuse and 7
of the 8 solid small bowel carcinomas showed gastro-
pancreatobiliary markers expression. Of note, all of
the 10 glandular cases with the non-intestinal
phenotype occurred in Crohn’s disease patients.
Survival analysis showed a favorable influence of
individual intestinal markers (especially CDX2
and MUC2) and a worse influence of gastro-
pancreatobiliary markers. The pyloric and Brunner’s
gland marker MUC6 was found in a small fraction
(16%) of cases, including 2 celiac disease-associated,
7 Crohn’s disease-associated and 3 sporadic small
bowel carcinomas, without a significant difference
among clinical groups (P=0.156) and without prog-
nostic value (hazard ratio: 0.80, 0.30–2.13, P=0.654).
Cumulative markers analysis showed better survi-
val for patients with tumors of essentially intestinal
phenotype compared with those expressing non-
intestinal markers (in at least 10% of cells) (Table 3).
This finding may contribute to the poor outcome of
Crohn’s disease-associated small bowel carcinoma
patients, most of which (20/25, 80%) showed
non-intestinal marker expression. In a stage-, sex-
and age-inclusive survival analysis of 75 small bowel
carcinomas, the favorable influence of intestinal
phenotype was retained (hazard ratio: 0.30,
0.14–0.69; P=0.004), while it lost significance when
the clinical group was also added to the model.
Figure 2 (a) Kaplan–Meier survival estimates for all 76 small
bowel carcinoma patients by histotype. Post hoc comparisons
(significance after Bonferroni’s correction set at Po0.005): (A)
significant differences: diffuse vs glandular: Po0.001; diffuse vs
medullary: P=0.003; glandular vs mixed: Po0.001; (B) non-
significant trends: medullary vs mixed: P=0.013; medullary vs
solid: P=0.064; glandular vs solid: P=0.088; (C) non-significant
differences: diffuse vs mixed: P=0.544; diffuse vs solid: P=0.170;
mixed vs solid: P=0.401; glandular vs medullary: P=0.207.
Notably, no difference was found between diffuse, mixed and
solid histotypes, which were pooled in panel (b). (b) Kaplan–Meier
survival estimates for the 70 non-medullary small bowel carci-
noma patients by glandular vs diffuse/mixed/solid histotype.
Table 2 Overall survival by a multivariable Cox model of the 75
small bowel carcinomas patients with complete stage data








Sporadic carcinomas 2.48 (0.66–9.29) 0.176a,b
Stages III–IV vs stages I–II 9.31 (3.30–26.26) o0.001
CD3+ tumor-infiltrating
lymphocytes 415/high-
power field vs ≤ 15
0.15 (0.03–0.69) 0.015
Glandular histotype vs non-
glandularc
0.37 (0.16–0.84) 0.018
Model: LR chi2(5) = 56.72, P-valueo0.001; Harrell’s C=0.87;
shrinkage coefficient = 0.91.
aFor post hoc comparisons among the clinical groups, significance
after Bonferroni’s correction set at 0.017.
bHazard ratio (95% CI): 0.50 (0.22–1.14), P-value = 0.098 vs Crohn’s
disease-associated small bowel carcinomas.
cMedullary histotype included among non-glandular cases.
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However, in a multivariable analysis, inclusive of
stage and microsatellite instability or tumor-
infiltrating lymphocytes, the intestinal phenotype
remained predictive of improved survival (hazard
ratio: 0.35, 0.16–0.77, P=0.009).
Impact of Microsatellite Instability and
Tumor-Infiltrating Lymphocytes on Prognostic
Power of Histotype and Phenotype
In a previous study,7 the small bowel carcinoma
microsatellite instability status (ascertained by con-
cordant MLH1 nuclear loss, molecular analysis and
MLH1 promoter hypermethylation) was found to be
associated with improved survival and to correlate
with tumor-infiltrating lymphocytes, the likely
microsatellite instability antitumor effectors.22,26
Thus when we found that both microsatellite
instability and high tumor-infiltrating lymphocyte
density were segregating among small bowel carci-
nomas showing glandular or medullary histotype
and intestinal phenotype, we investigated for any
potential impact of microsatellite instability and/or
high tumor-infiltrating lymphocytes on the prognos-
tic power of histotype and phenotype. Separation of
25 cases showing microsatellite instability, 28 cases
with high tumor-infiltrating lymphocytes or 19 cases
showing both microsatellite instability and high
tumor-infiltrating lymphocytes from the remaining
small bowel carcinomas gave highly significant
survival differences (hazard ratio: 0.22, 0.08–0.64,
P=0.005; hazard ratio: 0.09, 0.02–0.36, Po0.001
and hazard ratio: 0.26, 0.12–0.57; Po0.001,
respectively). Survival analysis of the 51 microsatel-
lite stable or the 48 low tumor-infiltrating
lymphocyte cases confirmed the importance of
histological structure and phenotype with an
improved survival of glandular vs diffuse/mixed/
solid cases (hazard ratio: 0.28, 0.12–0.63, P=0.002
among microsatellite stable cases and hazard ratio:
0.40, 0.18–0.87, P=0.022 among low tumor-
infiltrating lymphocyte cases, respectively) and of
intestinal vs non-intestinal phenotype small bowel
carcinoma cases (hazard ratio: 0.50, 0.23–1.08,
P=0.080 and hazard ratio: 0.41, 0.19–0.89,
P=0.023, respectively).
Small Bowel Carcinoma Expression of Nuclear
b-Catenin and SOX-9
As shown in Table 4 and Figures 4a and b, nuclear
β-catenin expression was significantly concentrated
within the celiac disease-associated small bowel
carcinoma group, which differed significantly from
the remaining small bowel carcinomas. Interestingly,
N-terminally directed antibodies failed to recognize
nuclear β-catenin in 17/40 (42%) tumors where the
protein was easily detected in the nucleus by
C-terminal antibodies. Both N- and C-terminal anti-
bodies recognized membranous β-catenin in normal
non-tumor mucosa of the same cases, thus suggesting
the possibility of a tumor-selective N-terminal
β-catenin loss. This was found to be unrelated to
patient background disease and survival (Table 4). A
relationship of our findings with the β-catenin gene
deletion reported by Breuhahn et al27 in some
sporadic small bowel carcinomas seems likely.
Similar to the nuclear β-catenin expression, the loss
of MLH1 expression (which overlapped perfectly
with molecularly assessed microsatellite instability
status) was also highly and selectively concentrated
among celiac disease-associated small bowel carcino-
mas (P=0.001 vs remaining small bowel carcinomas).
In fact, a correlation was found among the whole
small bowel cancer series between the distribution of
the two changes (Po0.001, Fisher’s test).
The nuclear expression of SOX-9, another
Wnt-related transcription factor, was significantly
Table 3 Expression of phenotypic markers in 76 small bowel carcinomas: their distribution among clinical groups and prognostic value











Cytokeratin 7 5 (19%)a 15 (60%)b 4 (16%) 24 (32%) 2.72 (1.18–6.29) 0.019
MUC5AC 5 (19%) 13 (52%) 5 (20%) 23 (30%) 2.54 (1.08–5.98) 0.032
CDX2 21 (81%)c 9 (36%) 17 (68%) 47 (62%) 0.28 (0.13–0.63) 0.002
MUC2 18 (69%) 12 (48%) 12 (48%) 42 (55%) 0.25 (0.12–0.53) o0.001
Cytokeratin 20 13 (50%) 9 (36%)d 20 (80%) 42 (55%) 1.19 (0.57–2.50) 0.635
CD10 8 (31%) 3 (12%) 11 (44%) 22 (29%) 0.66 (0.30–1.65) 0.302
Intestinal
phenotype
17 (65%)e 5 (20%)f 17 (68%) 39 (51%) 0.39 (0.18–0.81)g 0.012
aP=0.004 vs Crohn’s disease-associated carcinomas.
bP=0.003 vs sporadic carcinomas.
cP=0.002 vs Crohn’s disease-associated carcinomas.
dP=0.004 vs sporadic carcinomas.
eP=0.002 vs Crohn’s disease-associated carcinomas.
fP=0.001 vs sporadic carcinomas.
gVs remaining 37 cases expressing gastro-pancreatobiliary markers.
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correlated with that of β-catenin (P=0.005, Fisher’s
test) and was also highly represented among celiac
disease-associated small bowel carcinomas (Figure 4c),
although less selectively than β-catenin. Indeed, no
significant difference for SOX-9 expression was found
among clinical groups. A trend for SOX-9 to be more
extensively expressed in intramucosal or superficial
than in deeply invasive tumor growths was noted.
Figure 3 Phenotypic marker expression in small bowel carcinomas. (a) Uniform and intense nuclear positivity for the intestinal
transcription factor CDX2 in a glandular-type celiac disease-associated carcinoma. (b) Luminal surface expression of the brush border
marker CD10 in a celiac disease-associated carcinoma. (c) A sporadic small bowel carcinoma reactive for the intestinal marker CK20. (d)
Signet ring cell Crohn’s disease-associated carcinoma reactive for the goblet cell mucin MUC2. (e) A glandular Crohn’s disease-associated
carcinoma extensively expressing the gastric foveolar marker MUC5AC. (f) A mixed-type Crohn’s disease-associated carcinoma reactive
for the pancreatobiliary duct marker CK7.
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Univariate survival analysis of the whole series
showed a significantly better survival for patients
bearing nuclear β-catenin-positive vs -negative small
bowel carcinoma, whereas SOX-9 failed to reveal
prognostic relevance. The association of nuclear
β-catenin with more favorable outcome was retained
in a stage-, age- and sex-inclusive multivariable
model (hazard ratio: 0.32, 0.13–0.75; P=0.010) or
in a stage- and histotype-inclusive model (hazard
ratio: 0.29, 0.13–0.65; P=0.003), while losing sig-
nificance only when clinical groups were added to
the model. However, when survival of 20 small
bowel carcinoma patients showing both microsatel-
lite instability and nuclear β-catenin was compared
with that of 20 cases showing nuclear β-catenin in
the absence of microsatellite instability, the latter
group had a worse outcome (hazard ratio: 7.14,
2.00–25.00; P=0.002). In addition, among the 51
microsatellite stable cases, the 20 β-catenin-positive
small bowel carcinoma cases lacked any survival
difference compared with 31 β-catenin-negative
small bowel carcinoma patients (hazard ratio: 0.66,
0.31–1.43; P=0.296).
Small Bowel Carcinoma-Associated Dysplasia and
Other Preneoplastic Changes
Evidence for residual adenomatous polypoid growth
was obtained, within or adjacent to the superficial
part of the neoplasm, in 10 of the 25 sporadic small
bowel carcinomas, 8 of the 25 Crohn’s disease-
associated carcinomas and only 1 of the 26 celiac
disease-associated carcinoma. Focal flat dysplasia,
usually adjacent to the invasive cancer focus, was
detected in 4 celiac disease-associated, 1 sporadic
and 5 Crohn’s disease-associated small bowel carci-
nomas (Figure 4d). Minute dysplastic foci were
Table 4 Small bowel carcinoma molecular alterations: distribution among clinical groups and survival analysis













24/26 (92%)a 6/24 (25%) 10/25 (40%) 40/75 (53%) 0.30 (0.14–0.63) 0.002
Nuclear N-terminal
β-catenin loss
10/26 (38%) 2/24 (8%) 5/25 (20%) 17/75 (23%) 0.49 (0.22–1.12)b 0.091
Among C-terminal
β –catenin-positive cases
10/24 (42%) 2/6 (33%) 5/10 (50%) 17/40 (42%) 0.85 (0.24–2.97)c 0.796
SOX-9 expression 20/23 (87%) 11/22 (50%) 14/23(51%) 45/68 (66%) 0.70 (0.31–1.56) 0.380
Microsatellite instabilityd 17/26 (65%)e 4/25 (16%) 4/25 (16%) 25/76 (33%) 0.22 (0.08–0.64) 0.005
Among C-terminal
β–catenin-positive cases
17/24 (71%)a 1/6 (17%) 2/10 (20%) 20/40 (50%) 0.14 (0.04–0.50) 0.002
aPo0.001 vs Crohn’s disease-associated carcinomas or sporadic carcinomas.
bVs remaining small bowel carcinomas.
cVs remaining C-terminal β-catenin-positive cases.
dAll 17 microsatellite unstable cases also had nuclear β-catenin among celiac disease-associated carcinomas; as against only one of the 4 among
Crohn’s disease-associated carcinomas and 2 of the 4 among sporadic carcinomas.
eP=0.001 vs Crohn’s disease-associated carcinomas or sporadic carcinomas.
Figure 4 Molecular/cellular marker expression and preneoplastic changes. (a, b) Nuclear accumulation of β-catenin in a celiac disease-
associated small bowel carcinoma (a), to be compared with a membranous/cytoplasmic reactivity of a Crohn’s disease-associated small
bowel carcinoma (b). (c) Intense SOX-9 expression in the tumor cell nuclei of a celiac disease-associated carcinoma. (d) Evidence for
residual high-grade dysplasia overlying the superficial part of an invasive celiac disease-associated small bowel carcinoma (arrowheads).
(e, f) Nuclear SOX-9 (e) and β-catenin (f) expression in a flat, low-grade, dysplastic lesion of a celiac disease-associated carcinoma case.
Note the villous atrophy and, in the inset of panel (e), the extensive nuclear SOX-9 reactivity of hyperplastic crypts adjacent to dysplasia.
(g) Same celiac disease-associated small bowel carcinoma case as in panel (d) showing discrepancy in MLH1 expression between the
dysplastic (positive) and the underlying, invasive (negative) components. (h) A normal jejunal mucosa adjacent to a sporadic small bowel
carcinoma with nuclear SOX-9 expression restricted to the deep-half of the crypts. Note a few enteroendocrine cells with SOX-9-reactive
cytoplasm and unreactive nucleus (arrows). (i) SOX-9 nuclear expression in the atrophic mucosa distant from a celiac disease-associated
small bowel carcinoma, showing a prominent SOX-9 expansion to involve the upper half of the crypts, the crypt/villous junction and even
the surface epithelium. (j) A focus of MUC5AC-positive, high-grade dysplasia of a Crohn’s disease-associated small bowel carcinoma case.
(k) A dysplastic lesion and an underlying small focus of diffuse type Crohn’s disease-associated small bowel carcinoma (arrowheads), both
concordantly reactive for CK7. (l) An isolated, ‘microscopic’ CK7-positive neoplastic lesion with focal stromal invasion in the small bowel
mucosa distant from a ‘macroscopic’ Crohn’s disease-associated small bowel carcinoma. (m) Diffuse and intense MUC5AC positivity of a
polypoid adenomatous dysplasia adjacent to a Crohn’s disease-associated small bowel carcinoma.
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found, in addition, associated with mucosal meta-
plastic changes in 3 Crohn’s disease-associated
carcinomas (see below). Total dysplastic lesions are
summarized in Table 5, where it appears that nuclear
SOX-9 (Figure 4e), found in 23/28 (82%) of cases
investigated, is the molecular marker most widely
expressed in dysplasia, irrespective of clinical group,
followed by p53 overexpression (15/29, 52%) and
β-catenin (10/29, 34%) (Figure 4f), with only 2 of the
29 (7%) dysplastic lesions showing MLH1 loss. On
the contrary, the latter change occurred in 24/76
(32%) carcinomas, including 5 of the cases retaining
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MLH1 staining in the corresponding dysplasia
(Figure 4g). This finding outlines a relatively late
appearance of microsatellite instability status during
carcinogenesis.
Diffuse or patchy celiac disease lesions, ie, goblet-
cell poor crypt hyperplasia plus increased intrae-
pithelial lymphocytes, either isolated (5/25) or
associated with villous atrophy (17/25), were seen
in the majority (22/25, 88%) of celiac disease-
associated small bowel carcinomas, both in cancer-
adjacent and cancer-distant small bowel mucosa.
Notably, nuclear SOX-9 expression, normally
restricted to the deep lower half of crypts
(Figure 4h), showed a prominent expansion to
involve the upper half of the crypts in non-tumor
mucosa of all 19 celiac disease-associated small
bowel carcinomas investigated, sometimes reaching
the crypt/villous junction or even to the superficial
epithelium covering the flattened mucosa resulting
from villous atrophy (Figure 4i). Care was taken to
discard chromogranin-A reactive cells, usually
showing SOX-9-positive cytoplasm in the absence
of nuclear staining and scattered as single elements
along the whole crypt–villous unit (Figure 4h).
Interestingly, direct continuity of SOX-9-reactive
crypt hyperplasia with dysplasia and intramucosal
neoplasia was consistently seen (Figure 4e). No
relevant change of nuclear β-catenin expression,
which remained restricted to very few cells inter-
posed with Paneth cells within the deepest crypts,
was observed in SOX-9-positive crypt hyperplasia.
However, intense nuclear β-catenin appeared in
adjacent dysplastic or neoplastic lesions (Figure 4f).
Although no preneoplastic change was identified in
non-tumor mucosa of sporadic small bowel carcino-
mas, metaplastic changes showing the expression of
the gastric foveolar marker MUC5AC and/or the
ductal pancreatobiliary marker CK7 were extensively
represented (86%) in the chronically inflamed, non-
neoplastic mucosa associated with Crohn’s disease-
associated small bowel carcinomas, sometimes
coupled with minute dysplastic or neoplastic foci
(Figure 4j). Notably, 93% of the overt dysplastic
lesions associated with Crohn’s disease-associated
carcinomas showed the expression of CK7 and/or
MUC5AC; moreover, the gastro-pancreatobiliary
markers were concordantly expressed in metaplastic,
dysplastic and invasive components of all but one of
the 15 Crohn’s disease-associated small bowel
carcinomas investigated (Figures 4k–m).
Discussion
In this study of small bowel carcinoma, retention of
intestinal phenotype and gland-forming capacity by
tumor cells was associated with better patient
survival compared with acquisition of non-
intestinal (metaplastic) phenotype or non-glandular
histological structure. In addition, a small group
of medullary-type microsatellite instability/high
tumor-infiltrating lymphocyte cancers, found to
have a good prognosis in accordance with previous
studies,28–30 were distinct from solid non-medullary
cancers. As a previous study7 showed that both high
tumor-infiltrating lymphocyte density and microsa-
tellite instability status were associated with
improved survival, the prognostic power of tumor
histology and phenotype was confirmed in the
microsatellite stable and/or low tumor-infiltrating
lymphocyte subpopulations of small bowel carci-
noma patients. The prognostic power of glandular
histology was also found to retain significance in a
multivariable model inclusive of stage, clinical
group and tumor-infiltrating lymphocyte density
(or microsatellite instability status).
When substituted for glandular histology in the
same model, the intestinal phenotype lost prognostic
power, which, however, was retained when the
clinical groups were eliminated from the model. It
should be noted that the group-independent behavior
of the glandular histotype fits with its relatively
uniform distribution among the groups, while the
group-sensitive behavior of the phenotype couples
with the high, selective expression of non-intestinal
Table 5 Analysis of dysplastic and metaplastic changes associated with small bowel carcinomas
Celiac disease carcinomas Crohn’s disease carcinomas Sporadic carcinomas Total
Dysplasia 5/26 (19%)a 16/25 (64%)b 11/25 (44%)c 32/76 (42%)
Metaplastic phenotyped 0/5 (0%) 14/15 (93%) 2/10 (20%) 16/30 (53%)
β-Catenin nuclear expression 5/5 (100%) 0/13 (0%) 5/11 (45%) 10/29 (34%)
SOX-9 expression 5/5 (100%) 10/13 (77%) 8/10 (80%) 23/28 (82%)
MLH1 loss 1/5 (20%) 1/14 (7%) 0/10 (0%) 2/29 (7%)
p53 overexpression 4/5 (80%) 7/15 (47%) 4/9 (44%) 15/29 (52%)
Non-dysplastic mucosa
Metaplastic phenotyped 2/25 (9%) 19/22 (86%)e 0/24 (0%) 21/71 (30%)
aPolypoid in one and flat in four cases.
bPolypoid in eight, flat in five and minute foci in metaplasia in three cases.
cPolypoid in 10 and flat in 1 case.
dMetaplastic phenotype was defined as extensive MUC5AC and/or cytokeratin 7 expression.
ePo0.001 vs either celiac disease-associated carcinomas or sporadic carcinomas.
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markers associated with worse prognosis among
Crohn’s disease-associated small bowel carcinomas.
The latter finding may well contribute to the poor
survival shown by Crohn’s disease-associated small
bowel carcinoma patients. Interestingly, the worse
survival of Crohn’s disease-associated carcinoma cases
reached full statistical significance only with respect
to celiac disease-associated carcinoma cases but not to
sporadic carcinoma cases. Indeed, the microsatellite
instability/high tumor-infiltrating lymphocytes pattern
of celiac disease-associated carcinoma is likely to
amplify its intestinal phenotype-dependent survival
improvement with respect to Crohn’s disease-
associated small bowel carcinoma cases.
The histotype and phenotype approaches pro-
posed here offer new tools for small bowel carci-
noma prognostic evaluation, and these should be
added to the clinical group characterization and
microsatellite instability status suggested by our
previous investigations.7 Notably, while both histo-
type and phenotype proved to be prognostic factors
independent of microsatellite instability and tumor-
infiltrating lymphocyte density, only histotype was
fully independent of clinical groups.
As expected, all small bowel carcinomas with
medullary-type histology, ie, a solid structure with
well-demarcated ‘pushing’ borders, had high tumor-
infiltrating lymphocytes. Five of the six cases also
had microsatellite instability status as a likely cause
of their increased tumor-infiltrating lymphocyte
density. Given the difficulty in separating, on
purely histological grounds, gut medullary from
lymphoepithelioma-like cancer,31 often associated
with Epstein–Barr virus infection, a separate
investigation tested the single microsatellite stable
case with Epstein–Barr virus-encoded small RNAs
in situ hybridization, finding it to be diffusely
positive.32
Similar to microsatellite instability, the nuclear
accumulation of β-catenin was also found to be
highly prevalent among celiac disease-associated
small bowel carcinomas and to be apparently
associated with improved survival. This seemed
surprising as, unlike microsatellite instability,
nuclear β-catenin expression has been reported by
studies of other neoplasms to imply a less than
favorable prognostic influence.33–35 However, when
among β-catenin-positive small bowel carcinomas,
microsatellite unstable and microsatellite stable
cases were compared or among microsatellite stable
carcinomas, β-catenin-positive and -negative cases
were compared, the lack of favorable prognostic
influence of β-catenin itself, in the absence of
microsatellite instability, became evident. The dis-
tributive association we found, especially among
celiac disease-associated carcinomas, between
nuclear β-catenin expression and the prognostic
favorable microsatellite instability status, might
account for this misleading prognostic influence of
β-catenin. Notably, such an association is at variance
with colorectal cancer findings, where nuclear
β-catenin expression, highly prevalent among micro-
satellite stable cases, due to CTNNB1 or APC point
mutations, has been reported to be rare in micro-
satellite unstable cases.36 Instead of point mutations,
large CTNNB1 N-terminal deletions have been
reported to stabilize β-catenin in 20% of sporadic
small bowel carcinomas,27 a finding we confirmed
by selective N- vs C-terminal β-catenin immunohis-
tochemistry in our sporadic small bowel carcinomas
and extended to about 40% of celiac disease-
associated small bowel carcinomas. Whether addi-
tional stabilization mechanisms may account for the
very high celiac disease-associated small bowel
carcinoma rate of nuclear β-catenin (around 90%)
and for its association with microsatellite instability
status, it remains to be further investigated. On the
other hand, the lack of BRAF mutations and the lack
of correlation between KRAS mutations and micro-
satellite instability found in previous small bowel
carcinoma studies5,7 rule out a role of these
oncogenes in inducing MLH1 gene methylation
and, consequently, microsatellite instability status,
as has been shown to occur in colorectal cancers.37,38
Thus more work is needed to explain the unusual
association between microsatellite instability status
and Wnt activation among celiac disease-associated
small bowel carcinomas.
We found that another Wnt-related protein, the
SOX-9 transcription factor, was also highly expressed
in small bowel carcinomas, with a distribution
comparable to that of nuclear β-catenin, at least
among celiac disease-associated small bowel carcino-
mas. This finding seems relevant, as SOX-9 high
expression has been reported in a number of cancers,
including colorectal, gastric, pancreatic, hepatocellu-
lar, brain, lung and prostate cancers.39 In some of
these cancers, SOX-9 expression was found to be
associated with tumor progression, invasion and
metastasis, a pattern not seen in our small bowel
carcinomas. However, an important SOX-9 role in
carcinogenesis has also been proposed,39 at least in
part through Wnt activation via frizzled and LRP
receptor overexpression.40,41 In keeping with this
hypothesis, SOX-9 overexpression has also been
reported in some precancerous conditions, including
metaplastic and dysplastic lesions of chronic Helico-
bacter pylori gastritis,42,43 chronic bladder injury44
and early stages of colorectal tumorigenesis,39 as well
as in ‘acute’ untreated adult celiac disease.45
This led us to investigate non-tumor mucosa of
small bowel carcinoma-bearing patients for SOX-9
expression. In most celiac disease-associated small
bowel carcinoma cases, we frequently observed signs
of persistent mucosal damage, including atrophy of
the villi, excessive intraepithelial T lymphocyte
infiltration and goblet cell-poor and relatively
immature crypt hyperplasia, not unlike those
reported in biopsies of some non-neoplastic adult
celiac disease patients, even when under gluten-free
diet.46 Notably, multifocal extension of nuclear
SOX-9 expression, usually involving the upper half
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of the hyperplastic crypts was found in most celiac
disease cases investigated, even in the mucosa at a
distance from the neoplasm. By itself, the topo-
graphic continuity we observed at some foci between
SOX-9-positive crypt hyperplasia and intramucosal
dysplastic or cancerous growths may be suggestive
for a histogenetic link between such lesions.
A role for SOX-9 in the mucosa repair process of
persistent celiac disease lesions seems conceivable
considering its known role in intestinal mucosal
repair from other types of damage.47 The SOX-9-
activating role of NF-κB transcription factor, as
ascertained, for instance, in experimental H. pylori
gastritis,43 seems especially important. Indeed, NF-κB
activity, in turn activated by pro-inflammatory cyto-
kines, has been shown to be enhanced in many
immune-inflammatory processes, including inflam-
matory bowel diseases and related carcinogenesis,48
as well as celiac disease.49 In fact, a switch from the
known SOX-9 role in adult stem cell modulation to
cancer stem cell activation, often chronic injury
promoted and involving constitutive oncogene activa-
tion or oncosuppressor gene silencing, has been
suggested by several studies.39,44,50–52
Our evidence of polypoid adenomatous remnants in
the superficial part of Crohn’s disease-associated and
sporadic small bowel carcinomas supports the
hypothesis that the adenoma-carcinoma sequence,
well known from colorectal neoplasms, is also
operative for these two types of small bowel
carcinoma.14,15,53 In celiac disease-associated
carcinomas, we obtained evidence for a possible
adenomatous polyp origin in only a single case, thus
confirming the previous finding54 of a substantial lack
of such lesions in celiac disease cases, while we
found four celiac disease-associated carcinomas with
flat dysplasia reactive for both nuclear β-catenin and
SOX-9.
Metaplastic changes showing the same gastric
and/or pancreatobiliary phenotype as found in the
associated cancer were frequent in dysplastic or non-
dysplastic mucosa adjacent to Crohn’s disease-
associated carcinomas, though not to celiac disease-
associated or sporadic carcinomas. This finding may
suggest a precancerous role of such lesions in
Crohn’s disease. Thus two distinct histogenetic
processes seem at work for celiac disease-
associated and Crohn’s disease-associated small
bowel carcinomas, starting from immature crypt
hyperplasia or epithelial metaplasia, respectively.
Although a more extensive, prospective and sys-
tematic search for hyperplastic, metaplastic and
dysplastic lesions is warranted for a better under-
standing of small bowel carcinoma histogenesis in the
two types of immune-inflammatory conditions we
studied, the present findings may indicate promising
lines of investigation to identify preneoplastic lesions
of potential help in early cancer diagnosis.
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